Compare ARVN & HIFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARVN | HIFS |
|---|---|---|
| Founded | 2015 | 1834 |
| Country | United States | United States |
| Employees | N/A | 97 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.2M | 622.1M |
| IPO Year | 2018 | N/A |
| Metric | ARVN | HIFS |
|---|---|---|
| Price | $7.57 | $280.80 |
| Analyst Decision | Buy | |
| Analyst Count | 19 | 0 |
| Target Price | ★ $15.05 | N/A |
| AVG Volume (30 Days) | ★ 694.3K | 19.8K |
| Earning Date | 05-04-2026 | 04-17-2026 |
| Dividend Yield | N/A | ★ 0.89% |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $12.63 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.06 | $220.76 |
| 52 Week High | $14.22 | $338.00 |
| Indicator | ARVN | HIFS |
|---|---|---|
| Relative Strength Index (RSI) | 37.96 | 47.08 |
| Support Level | $7.35 | $258.71 |
| Resistance Level | $10.18 | $295.70 |
| Average True Range (ATR) | 0.42 | 10.73 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 31.43 | 23.12 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Hingham Institution for Savings is a Massachusetts-chartered savings bank headquartered in Hingham, Massachusetts. The bank is principally engaged in the business of commercial and residential real estate mortgage lending, funded by a mix of retail and commercial deposits, wholesale deposits and borrowings. Its primary deposit products are savings, checking, and term certificate accounts, and its primary lending products are residential and commercial mortgage loans secured by properties in eastern Massachusetts. The bank also lends to commercial and residential real estate borrowers and services deposits for customers in the greater Washington, D.C. metropolitan area (WMA) and in the San Francisco Bay Area.